The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).
 
Chee Khoon Lee
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim
 
Shalini Subramaniam
No Relationships to Disclose
 
Antony Mersiades
Consulting or Advisory Role - Boehringer Ingelheim
Travel, Accommodations, Expenses - Roche
 
Jenna Mitchell
No Relationships to Disclose
 
Hannora Jurkovic
Employment - Novartis (I)
 
Mariya Walker
No Relationships to Disclose
 
Loc Le
No Relationships to Disclose
 
Chris Brown
No Relationships to Disclose
 
Benjamin J. Solomon
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Loxo; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Veristrat (Biodesix); UpToDate
 
Tom John
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; AstraZeneca/MedImmune; Boehringer Ingelheim; Ignyta; Merck KGaA; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche; Roche
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Bin-Chi Liao
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; G1 Therapeutics; Hansoh; Incyte; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Takeda; Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Chao-Hua Chiu
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Roche